{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T17:29:19Z","timestamp":1784914159321,"version":"3.55.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-10820-9","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T12:56:10Z","timestamp":1752670570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of cerebrolysin on behavioral changes and the tryptophan-kynurenine pathway in the prefrontal cortex of male mice in the ketamine model of schizophrenia"],"prefix":"10.1007","volume":"52","author":[{"given":"Vida","family":"Mafikandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4203-4618","authenticated-orcid":false,"given":"Leila","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemehsadat","family":"Seyedaghamiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haniyeh","family":"Mansourian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parviz","family":"Shahabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjad","family":"Taghizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3731-7146","authenticated-orcid":false,"given":"Ali","family":"Fakhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"10820_CR1","doi-asserted-by":"publisher","first-page":"45094","DOI":"10.4088\/JCP.MS21078COM5","volume":"84","author":"DI Velligan","year":"2023","unstructured":"Velligan DI, Rao S (2023) The epidemiology and global burden of schizophrenia. J Clin Psychiatry 84:45094","journal-title":"J Clin Psychiatry"},{"key":"10820_CR2","doi-asserted-by":"publisher","first-page":"766692","DOI":"10.3389\/fpsyt.2021.766692","volume":"12","author":"SN Mosolov","year":"2022","unstructured":"Mosolov SN, Yaltonskaya PA (2022) Primary and secondary negative symptoms in schizophrenia. Front Psychiatry 12:766692. https:\/\/doi.org\/10.3389\/fpsyt.2021.766692","journal-title":"Front Psychiatry"},{"key":"10820_CR3","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s11011-017-9982-7","volume":"32","author":"B Kanchanatawan","year":"2017","unstructured":"Kanchanatawan B, Sirivichayakul S, Thika S, Ruxrungtham K, Carvalho AF, Geffard M, Anderson G, Noto C, Ivanova R, Maes M (2017) Physio-somatic symptoms in schizophrenia: association with depression, anxiety, neurocognitive deficits and the Tryptophan catabolite pathway. Metab Brain Dis 32:1003\u20131016. https:\/\/doi.org\/10.1007\/s11011-017-9982-7","journal-title":"Metab Brain Dis"},{"key":"10820_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.pnpbp.2012.07.016","volume":"42","author":"G Anderson","year":"2013","unstructured":"Anderson G, Maes M, Berk M (2013) Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and Tryptophan catabolite pathways. Prog Neuropsychopharmacol Biol Psychiatry 42:101\u2013114. https:\/\/doi.org\/10.1016\/j.pnpbp.2012.07.016","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10820_CR5","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.brainresbull.2021.01.021","volume":"170","author":"SS Valvassori","year":"2021","unstructured":"Valvassori SS, Cararo JH, Menegas S, Possamai-Della T, Aguiar-Geraldo JM, Araujo SL, Mastella GA, Quevedo J, Zugno AI (2021) Haloperidol elicits oxidative damage in the brain of rats submitted to the ketamine-induced model of schizophrenia. Brain Res Bull 170:246\u2013253. https:\/\/doi.org\/10.1016\/j.brainresbull.2021.01.021","journal-title":"Brain Res Bull"},{"key":"10820_CR6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ibneur.2023.12.012","volume":"16","author":"AH Moghaddam","year":"2024","unstructured":"Moghaddam AH, Estalkhi FM, Jelodar SK, Hasan TA, Farhadi-Pahnedari S, Karimian M (2024) Neuroprotective effects of alpha-pinene against behavioral deficits in ketamine-induced mice model of schizophrenia: focusing on oxidative stress status. IBRO Neurosci Rep 16:182\u2013189. https:\/\/doi.org\/10.1016\/j.ibneur.2023.12.012","journal-title":"IBRO Neurosci Rep"},{"key":"10820_CR7","doi-asserted-by":"publisher","unstructured":"Ebrahimi M, Ahangar N, Zamani E, Shaki F (2023) L-Carnitine prevents behavioural alterations in Ketamine\u2010Induced schizophrenia in mice: possible involvement of oxidative stress and inflammation pathways. J Toxicol 2023(9093231). https:\/\/doi.org\/10.1155\/2023\/9093231","DOI":"10.1155\/2023\/9093231"},{"key":"10820_CR8","doi-asserted-by":"publisher","first-page":"107079","DOI":"10.1016\/j.ntt.2022.107079","volume":"91","author":"X-j Li","year":"2022","unstructured":"Li X-j, Yu J-h, Wu X, Zhu X-m, Lv P, Du Z, Lu Y, Wu X, Yao J (2022) Ketamine enhances dopamine D1 receptor expression by modulating MicroRNAs in a ketamine-induced schizophrenia-like mouse model. Neurotoxicol Teratol 91:107079. https:\/\/doi.org\/10.1016\/j.ntt.2022.107079","journal-title":"Neurotoxicol Teratol"},{"key":"10820_CR9","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.3390\/ijms23052810","volume":"23","author":"A Vall\u00e9e","year":"2022","unstructured":"Vall\u00e9e A (2022) Neuroinflammation in schizophrenia: the key role of the WNT\/\u03b2-catenin pathway. Int J Mol Sci 23:2810. https:\/\/doi.org\/10.3390\/ijms23052810","journal-title":"Int J Mol Sci"},{"key":"10820_CR10","doi-asserted-by":"publisher","first-page":"114336","DOI":"10.1016\/j.intimp.2025.114336","volume":"151","author":"Z Huang","year":"2025","unstructured":"Huang Z, Chen G, Ren Z, Xiao L, Chen Z, Xie Y, Wang G, Zhou B (2025) Urolithin A ameliorates schizophrenia-like behaviors and cognitive impairments in female rats by modulating NLRP3 signaling. Int Immunopharmacol 151:114336. https:\/\/doi.org\/10.1016\/j.intimp.2025.114336","journal-title":"Int Immunopharmacol"},{"key":"10820_CR11","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1038\/s41380-019-0401-9","volume":"25","author":"J Kindler","year":"2020","unstructured":"Kindler J, Lim CK, Weickert CS, Boerrigter D, Galletly C, Liu D, Jacobs KR, Balzan R, Bruggemann J, O\u2019Donnell M (2020) Dysregulation of kynurenine metabolism is related to Proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia. Mol Psychiatry 25:2860\u20132872. https:\/\/doi.org\/10.1038\/s41380-019-0401-9","journal-title":"Mol Psychiatry"},{"key":"10820_CR12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.neuropharm.2016.02.029","volume":"112","author":"NH Hunt","year":"2017","unstructured":"Hunt NH, Too LK, Khaw LT, Guo J, Hee L, Mitchell AJ, Grau GE, Ball HJ (2017) The kynurenine pathway and parasitic infections that affect CNS function. Neuropharmacology 112:389\u2013398. https:\/\/doi.org\/10.1016\/j.neuropharm.2016.02.029","journal-title":"Neuropharmacology"},{"key":"10820_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.neubiorev.2021.01.018","volume":"123","author":"B Cao","year":"2021","unstructured":"Cao B, Chen Y, Ren Z, Pan Z, McIntyre RS, Wang D (2021) Dysregulation of kynurenine pathway and potential dynamic changes of kynurenine in schizophrenia: A systematic review and meta-analysis. Neurosci Biobehav Rev 123:203\u2013214. https:\/\/doi.org\/10.1016\/j.neubiorev.2021.01.018","journal-title":"Neurosci Biobehav Rev"},{"key":"10820_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41380-019-0414-4","volume":"25","author":"J Savitz","year":"2020","unstructured":"Savitz J (2020) The kynurenine pathway: a finger in every pie. Mol Psychiatry 25:131\u2013147","journal-title":"Mol Psychiatry"},{"key":"10820_CR15","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrn3257","volume":"13","author":"R Schwarcz","year":"2012","unstructured":"Schwarcz R, Bruno JP, Muchowski PJ, Wu H-Q (2012) Kynurenines in the mammalian brain: when physiology Meets pathology. Nat Rev Neurosci 13:465\u2013477. https:\/\/doi.org\/10.1038\/nrn3257","journal-title":"Nat Rev Neurosci"},{"key":"10820_CR16","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.neuint.2008.01.013","volume":"52","author":"CL Miller","year":"2008","unstructured":"Miller CL, Llenos IC, Cwik M, Walkup J, Weis S (2008) Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder. Neurochem Int 52:1297\u20131303. https:\/\/doi.org\/10.1016\/j.neuint.2008.01.013","journal-title":"Neurochem Int"},{"key":"10820_CR17","doi-asserted-by":"publisher","first-page":"eaaf9794","DOI":"10.1126\/science.aaf9794","volume":"357","author":"I Cervenka","year":"2017","unstructured":"Cervenka I, Agudelo LZ, Ruas JL (2017) Kynurenines: tryptophan\u2019s metabolites in exercise, inflammation, and mental health. Science 357:eaaf9794. https:\/\/doi.org\/10.1126\/science.aaf9794","journal-title":"Science"},{"key":"10820_CR18","doi-asserted-by":"crossref","unstructured":"\u00c1lvarez XA, Lombardi V, Fern\u00e1ndez-Novoa L, Garc\u00eda M, Sampedro C, Cagiao A, Cacabelos R, Windisch M (2000) Cerebrolysin\u00ae reduces microglial activation in vivo and in vitro: a potential mechanism of neuroprotection. Springer","DOI":"10.1007\/978-3-7091-6781-6_30"},{"key":"10820_CR19","doi-asserted-by":"publisher","first-page":"691","DOI":"10.4236\/pp.2014.57079","volume":"5","author":"G Flores","year":"2014","unstructured":"Flores G, Atzori M (2014) The potential of cerebrolysin in the treatment of schizophrenia. Pharmacol Pharm 5:691\u2013704","journal-title":"Pharmacol Pharm"},{"key":"10820_CR20","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/med.21960","volume":"43","author":"K Rejdak","year":"2023","unstructured":"Rejdak K, Sienkiewicz-Jarosz H, Bienkowski P, Alvarez A (2023) Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: effects of cerebrolysin. Med Res Rev 43:1668\u20131700. https:\/\/doi.org\/10.1002\/med.21960","journal-title":"Med Res Rev"},{"key":"10820_CR21","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1113\/EP088254","volume":"105","author":"J Ghazizadeh","year":"2020","unstructured":"Ghazizadeh J, Hamedeyazdan S, Torbati M, Farajdokht F, Fakhari A, Mahmoudi J, Araj-khodaei M, Sadigh\u2010Eteghad S (2020) Melissa officinalis L. hydro\u2010alcoholic extract inhibits anxiety and depression through prevention of central oxidative stress and apoptosis. Exp Physiol 105:707\u2013720. https:\/\/doi.org\/10.1113\/EP088254","journal-title":"Exp Physiol"},{"key":"10820_CR22","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s11033-021-06195-2","volume":"48","author":"F Seyedaghamiri","year":"2021","unstructured":"Seyedaghamiri F, Farajdokht F, Vatandoust SM, Mahmoudi J, Khabbaz A, Sadigh-Eteghad S (2021) Sericin modulates learning and memory behaviors by tuning of antioxidant, inflammatory, and apoptotic markers in the hippocampus of aged mice. Mol Biol Rep 48:1371\u20131382. https:\/\/doi.org\/10.1007\/s11033-021-06195-2","journal-title":"Mol Biol Rep"},{"key":"10820_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2023.11.015","volume":"264","author":"R Tandon","year":"2024","unstructured":"Tandon R, Nasrallah H, Akbarian S, Carpenter WT Jr, DeLisi LE, Gaebel W, Green MF, Gur RE, Heckers S, Kane JM (2024) The schizophrenia syndrome, circa 2024: what we know and how that informs its nature. Schizophr Res 264:1\u201328. https:\/\/doi.org\/10.1016\/j.schres.2023.11.015","journal-title":"Schizophr Res"},{"key":"10820_CR24","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1176\/ajp.155.8.1049","volume":"155","author":"RW Buchanan","year":"1998","unstructured":"Buchanan RW, Vladar K, Barta PE, Pearlson GD (1998) Structural evaluation of the prefrontal cortex in schizophrenia. Am J Psychiatry 155:1049\u20131055","journal-title":"Am J Psychiatry"},{"key":"10820_CR25","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1176\/appi.ajp.158.7.1105","volume":"158","author":"WM Perlstein","year":"2001","unstructured":"Perlstein WM, Carter CS, Noll DC, Cohen JD (2001) Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. Am J Psychiatry 158:1105\u20131113. https:\/\/doi.org\/10.1176\/appi.ajp.158.7.1105","journal-title":"Am J Psychiatry"},{"key":"10820_CR26","doi-asserted-by":"publisher","first-page":"S465","DOI":"10.1038\/bjp.2008.24","volume":"153","author":"J Pratt","year":"2008","unstructured":"Pratt J, Winchester C, Egerton A, Cochran S, Morris B (2008) Modelling prefrontal cortex deficits in schizophrenia: implications for treatment. Br J Pharmacol 153:S465\u2013S470. https:\/\/doi.org\/10.1038\/bjp.2008.24","journal-title":"Br J Pharmacol"},{"key":"10820_CR27","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/0269881113512909","volume":"28","author":"J Frohlich","year":"2014","unstructured":"Frohlich J, Van Horn JD (2014) Reviewing the ketamine model for schizophrenia. J Psychopharmacol 28:287\u2013302. https:\/\/doi.org\/10.1177\/0269881113512909","journal-title":"J Psychopharmacol"},{"key":"10820_CR28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.pbb.2017.12.004","volume":"165","author":"FA Guarraci","year":"2018","unstructured":"Guarraci FA, Gonzalez CM, Lucero D, Womble PD, Abdel-Rahim H, DeVore J, Kunkel MN, Quadlander E, Stinnett M, Boyette-Davis J (2018) The effects of ketamine on sexual behavior, anxiety, and locomotion in female rats. Pharmacol Biochem Behav 165:36\u201344. https:\/\/doi.org\/10.1016\/j.pbb.2017.12.004","journal-title":"Pharmacol Biochem Behav"},{"key":"10820_CR29","first-page":"31","volume":"19","author":"A Hajizadeh Moghaddam","year":"2016","unstructured":"Hajizadeh Moghaddam A, kianmehr A (2016) The protective effect of quince (Cydonia oblonga Miller) leaf extract on locomotor activity and Anxiety-Like behaviors in a ketamine model of schizophrenia. J Arak Univ Med Sci 19:31\u201341","journal-title":"J Arak Univ Med Sci"},{"key":"10820_CR30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/0004867411433213","volume":"46","author":"X Shifu","year":"2012","unstructured":"Shifu X, Haibo X, Guanjun L, Chengmei Y, Xia L, Chao C, Wu HZY, Mitchell P, Mingyuan Z (2012) Therapeutic effects of cerebrolysin added to Risperidone in patients with schizophrenia dominated by negative symptoms. Aust N Z J Psychiatry 46:153\u2013160","journal-title":"Aust N Z J Psychiatry"},{"key":"10820_CR31","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.psychres.2018.10.008","volume":"270","author":"KH Alzoubi","year":"2018","unstructured":"Alzoubi KH, Al-Ibbini AM, Nuseir KQ (2018) Prevention of memory impairment induced by post-traumatic stress disorder by cerebrolysin. Psychiatry Res 270:430\u2013437. https:\/\/doi.org\/10.1016\/j.psychres.2018.10.008","journal-title":"Psychiatry Res"},{"key":"10820_CR32","doi-asserted-by":"publisher","first-page":"109329","DOI":"10.1016\/j.cbi.2020.109329","volume":"334","author":"SA El-Marasy","year":"2021","unstructured":"El-Marasy SA, El Awdan SA, Hassan A, Ahmed-Farid OA, Ogaly HA (2021) Anti-depressant effect of cerebrolysin in reserpine-induced depression in rats: behavioral, biochemical, molecular and immunohistochemical evidence. Chem Biol Interact 334:109329. https:\/\/doi.org\/10.1016\/j.cbi.2020.109329","journal-title":"Chem Biol Interact"},{"key":"10820_CR33","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jpsychires.2024.02.029","volume":"172","author":"AO Abdelaty","year":"2024","unstructured":"Abdelaty AO, Tharwat EK, Abdelrahman AI, Elgohary A, Elsaeed H, El-Feky AS, Ebrahim YM, Habib A, Abd El Latif H, Khadrawy YA (2024) Cerebrolysin potentiates the antidepressant effect of lithium in a rat model of depression. J Psychiatr Res 172:171\u2013180. https:\/\/doi.org\/10.1016\/j.jpsychires.2024.02.029","journal-title":"J Psychiatr Res"},{"key":"10820_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-020-1721-z","volume":"17","author":"B Pedraz-Petrozzi","year":"2020","unstructured":"Pedraz-Petrozzi B, Elyamany O, Rummel C, Mulert C (2020) Effects of inflammation on the kynurenine pathway in schizophrenia\u2014a systematic review. J Neuroinflammation 17:1\u201317. https:\/\/doi.org\/10.1186\/s12974-020-1721-z","journal-title":"J Neuroinflammation"},{"key":"10820_CR35","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1038\/s41380-020-00951-9","volume":"26","author":"W Marx","year":"2021","unstructured":"Marx W, McGuinness AJ, Rocks T, Ruusunen A, Cleminson J, Walker AJ, Gomes-da-Costa S, Lane M, Sanches M, Diaz AP (2021) The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies. Mol Psychiatry 26:4158\u20134178. https:\/\/doi.org\/10.1038\/s41380-020-00951-9","journal-title":"Mol Psychiatry"},{"key":"10820_CR36","doi-asserted-by":"publisher","first-page":"897","DOI":"10.4314\/tjpr.v18i4.30","volume":"18","author":"Y Wang","year":"2019","unstructured":"Wang Y, Yuan X, Kang Y, Song X (2019) Tryptophan-kynurenine pathway as a novel link between gut microbiota and schizophrenia: A review. Trop J Pharm Res 18:897\u2013905","journal-title":"Trop J Pharm Res"},{"key":"10820_CR37","first-page":"161","volume":"11","author":"R Singh","year":"2019","unstructured":"Singh R (2019) Role of Tryptophan in health and disease: systematic review of the anti-oxidant, anti-inflammation, and nutritional aspects of Tryptophan and its metabolites. World Heart J 11:161\u2013178","journal-title":"World Heart J"},{"key":"10820_CR38","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1038\/npp.2016.66","volume":"41","author":"J Chiappelli","year":"2016","unstructured":"Chiappelli J, Postolache TT, Kochunov P, Rowland LM, Wijtenburg SA, Shukla DK, Tagamets M, Du X, Savransky A, Lowry CA (2016) Tryptophan metabolism and white matter integrity in schizophrenia. Neuropsychopharmacology 41:2587\u20132595. https:\/\/doi.org\/10.1038\/npp.2016.66","journal-title":"Neuropsychopharmacology"},{"key":"10820_CR39","doi-asserted-by":"publisher","first-page":"e1115","DOI":"10.1038\/tp.2017.88","volume":"7","author":"B Wurfel","year":"2017","unstructured":"Wurfel B, Drevets W, Bliss S, McMillin J, Suzuki H, Ford B, Morris H, Teague T, Dantzer R, Savitz J (2017) Serum kynurenic acid is reduced in affective psychosis. Transl Psychiatry 7:e1115\u2013e1115","journal-title":"Transl Psychiatry"},{"key":"10820_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12640-017-9714-0","volume":"32","author":"K Szymona","year":"2017","unstructured":"Szymona K, Zdzisi\u0144ska B, Karaku\u0142a-Juchnowicz H, Kocki T, Kandefer-Szersze\u0144 M, Flis M, Rosa W, Urba\u0144ska EM (2017) Correlations of kynurenic acid, 3-hydroxykynurenine, sIL-2R, IFN-\u03b1, and IL-4 with clinical symptoms during acute relapse of schizophrenia. Neurotox Res 32:17\u201326. https:\/\/doi.org\/10.1007\/s12640-017-9714-0","journal-title":"Neurotox Res"},{"key":"10820_CR41","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1017\/S1461145710001689","volume":"14","author":"R Condray","year":"2011","unstructured":"Condray R, Dougherty GG Jr, Keshavan MS, Reddy RD, Haas GL, Montrose DM, Matson WR, McEvoy J, Kaddurah-Daouk R, Yao JK (2011) 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int J Neuropsychopharmacol 14:756\u2013767. https:\/\/doi.org\/10.1017\/S1461145710001689","journal-title":"Int J Neuropsychopharmacol"},{"key":"10820_CR42","doi-asserted-by":"publisher","first-page":"e2738","DOI":"10.1002\/hup.2738","volume":"35","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Zhang M, Luo Y, Ni X, Lu H, Wen Y, Fan N (2020) Preliminary comparative analysis of kynurenine pathway metabolites in chronic ketamine users, schizophrenic patients, and healthy controls. Hum Psychopharmacology: Clin Experimental 35:e2738. https:\/\/doi.org\/10.1002\/hup.2738","journal-title":"Hum Psychopharmacology: Clin Experimental"},{"key":"10820_CR43","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/s0024-3205(02)01853-2","volume":"71","author":"M Maes","year":"2002","unstructured":"Maes M, Verkerk R, Bonaccorso S, Ombelet W, Bosmans E, Scharp\u00e9 S (2002) Depressive and anxiety symptoms in the early puerperium are related to increased degradation of Tryptophan into kynurenine, a phenomenon which is related to immune activation. Life Sci 71:1837\u20131848. https:\/\/doi.org\/10.1016\/s0024-3205(02)01853-2","journal-title":"Life Sci"},{"key":"10820_CR44","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/mp.2012.110","volume":"18","author":"S Fillman","year":"2013","unstructured":"Fillman S, Cloonan N, Catts V, Miller L, Wong J, McCrossin T, Cairns M, Weickert CS (2013) Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry 18:206\u2013214. https:\/\/doi.org\/10.1038\/mp.2012.110","journal-title":"Mol Psychiatry"},{"key":"10820_CR45","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jad.2021.03.062","volume":"287","author":"AF Almulla","year":"2021","unstructured":"Almulla AF, Al-Rawi KF, Maes M, Al-Hakeim HK (2021) In schizophrenia, immune-inflammatory pathways are strongly associated with depressive and anxiety symptoms, which are part of a latent trait which comprises neurocognitive impairments and schizophrenia symptoms. J Affect Disord 287:316\u2013326. https:\/\/doi.org\/10.1016\/j.jad.2021.03.062","journal-title":"J Affect Disord"},{"key":"10820_CR46","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2174\/1570159X15666171123201142","volume":"16","author":"JC Felger","year":"2018","unstructured":"Felger JC (2018) Imaging the role of inflammation in mood and anxiety-related disorders. Curr Neuropharmacol 16:533\u2013558. https:\/\/doi.org\/10.2174\/1570159X15666171123201142","journal-title":"Curr Neuropharmacol"},{"key":"10820_CR47","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1007\/s11064-015-1745-4","volume":"41","author":"Y Yang","year":"2016","unstructured":"Yang Y, Zhang Y, Wang Z, Wang S, Gao M, Xu R, Liang C, Zhang H (2016) Attenuation of acute phase injury in rat intracranial hemorrhage by cerebrolysin that inhibits brain edema and inflammatory response. Neurochem Res 41:748\u2013757. https:\/\/doi.org\/10.1007\/s11064-015-1745-4","journal-title":"Neurochem Res"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10820-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10820-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10820-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T04:26:43Z","timestamp":1766896003000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10820-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10820"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10820-9","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"26 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments were conducted according to the care and utilization of laboratory animals outlined in the Guide from the National Institutes of Health (NIH; Publication No. 85\u2009\u2212\u200923, Revised 1985), and these practices received approval from the Animal Care Committees at Tabriz Medical University (IR.TBZMED.AEC.1402.067).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"723"}}